Friday, 5 October 2012

Quinaretic


Pronunciation: KWIN-a-pril/HYE-droe-KLOR-oh-THYE-a-zide
Generic Name: Quinapril/Hydrochlorothiazide
Brand Name: Examples include Accuretic and Quinaretic

When used during the second and third trimesters of pregnancy, Quinaretic can cause injury or death to the fetus. If you think you may be pregnant, contact your doctor right away.





Quinaretic is used for:

Treating high blood pressure. It may also be used for other conditions as determined by your doctor.


Quinaretic is an angiotensin-converting enzyme (ACE) inhibitor and thiazide diuretic combination. It works by causing blood vessels to relax (widen) and increasing the excretion of excess fluid, which lowers blood pressure.


Do NOT use Quinaretic if:


  • you are allergic to any ingredient in Quinaretic or any other sulfonamide medicine (eg, glyburide, probenecid, sulfamethoxazole)

  • you have a history of angioedema (swelling of the hands, face, lips, eyes, throat, or tongue; difficulty swallowing or breathing; or hoarseness) caused by treatment with an ACE inhibitor

  • you are pregnant

  • you have severe kidney problems or are unable to urinate

  • you are taking dextran sulfate, dofetilide, or ketanserin

Contact your doctor or health care provider right away if any of these apply to you.



Before using Quinaretic:


Some medical conditions may interact with Quinaretic. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are able to become pregnant

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of heart problems (eg, heart failure, aortic stenosis), blood vessel problems (eg, in the brain or heart), blood flow problems, bone marrow problems, kidney problems (eg, renal artery stenosis), liver problems, or angioedema (swelling of the hands, face, lips, eyes, throat, or tongue; difficulty swallowing or breathing; or hoarseness)

  • if you have a history of a stroke, recent heart attack, or kidney transplant

  • if you have an autoimmune disease (eg, rheumatoid arthritis, lupus, scleroderma)

  • if you are dehydrated or have low blood volume

  • if you have high potassium levels, low blood sodium levels, high blood cholesterol or lipid levels, gout, or are on a low-salt (sodium) diet

  • if you have diabetes, especially if you are also taking aliskiren

  • if you are receiving treatments to reduce sensitivity to bee or wasp stings

  • if you are scheduled to have major surgery or to receive anesthesia, have recently had a certain type of nerve surgery (sympathectomy), or are on dialysis

  • if you have never taken another medicine for high blood pressure

Some MEDICINES MAY INTERACT with Quinaretic. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Aldosterone blockers (eg, eplerenone), aliskiren, potassium-sparing diuretics (eg, amiloride, spironolactone), potassium supplements, or salt substitutes containing potassium because the risk of high blood potassium levels may be increased

  • Angiotensin receptor blockers (eg, losartan) because the risk of serious kidney problems and high blood potassium levels may be increased

  • Gold-containing medicines (eg, auranofin, sodium aurothiomalate) because flushing, nausea, vomiting, and low blood pressure may occur

  • Adrenocorticotropic hormone (ACTH), barbiturates (eg, phenobarbital), corticosteroids (eg, prednisone), diazoxide, diuretics (eg, furosemide), narcotic pain medicines (eg, codeine), or other medicines for high blood pressure (eg, propranolol, verapamil) because they may increase the risk of Quinaretic's side effects

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, indomethacin) or salicylates (eg, aspirin) because they may decrease the effectiveness of Quinaretic

  • Dextran sulfate, digoxin, dofetilide, ketanserin, lithium, or thiopurines (eg, azathioprine) because the risk of their side effects may be increased by Quinaretic

  • Insulin, oral hypoglycemics (eg, glyburide), or tetracycline because their effectiveness may be decreased by Quinaretic

This may not be a complete list of all interactions that may occur. Ask your health care provider if Quinaretic may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Quinaretic:


Use Quinaretic as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Quinaretic by mouth with or without food.

  • Quinaretic may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.

  • If you are taking a tetracycline antibiotic, a quinolone antibiotic (eg, ciprofloxacin, levofloxacin), or colestipol or cholestyramine for high cholesterol, ask your doctor or pharmacist how to take it with Quinaretic. This product contains magnesium, which can interfere with absorption of these medicines.

  • Take Quinaretic on a regular schedule to get the most benefit from it.

  • Taking Quinaretic at the same time each day will help you remember to take it.

  • Continue to take Quinaretic even if you feel well. Do not miss any doses.

  • If you miss a dose of Quinaretic, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Quinaretic.



Important safety information:


  • Quinaretic may cause drowsiness, dizziness, light-headedness, or fainting. These effects may be worse if you take it with alcohol or certain medicines. Use Quinaretic with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Quinaretic may cause dizziness, light-headedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Report any light-headedness or fainting to your doctor immediately. Your risk of light-headedness or fainting may be increased if you experience diarrhea, vomiting, or excessive sweating, if you do not drink enough fluids, or if you are on a low-salt (sodium) diet.

  • Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.

  • Quinaretic has magnesium in it. Before you start any new medicine, check the label to see if it has magnesium in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Quinaretic may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Quinaretic. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Quinaretic may cause a serious side effect called angioedema. Black patients may be at greater risk of developing this side effect. Contact your doctor at once if you develop swelling of the hands, face, lips, eyes, throat, or tongue; difficulty swallowing or breathing; or hoarseness.

  • Quinaretic contains hydrochlorothiazide, a sulfonamide, which can cause certain eye problems (myopia, angle-closure glaucoma). Your risk may be increased if you are allergic to sulfonamide medicines (eg, sulfamethoxazole) or to penicillin antibiotics (eg, amoxicillin). Untreated angle-closure glaucoma can lead to permanent vision loss. If these eye problems occur, symptoms usually occur within hours to weeks of starting Quinaretic. Contact your doctor immediately if you experience symptoms such as vision changes (eg, decreased vision clearness) or eye pain.

  • Dehydration, excessive sweating, vomiting, or diarrhea may lead to a fall in blood pressure. Contact your health care provider at once if any of these symptoms occur.

  • Check with your doctor before you use a salt substitute or a product that has potassium in it.

  • Quinaretic may lower the ability of your body to fight infection. Avoid contact with people who have colds or infections. Tell your doctor if you notice signs of infection like fever, sore throat, rash, or chills.

  • It may take 1 to 2 weeks for Quinaretic to work. Do not stop taking Quinaretic without checking with your doctor.

  • Tell your doctor or dentist that you take Quinaretic before you receive any medical or dental care, emergency care, or surgery.

  • Diabetes patients - Quinaretic may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

  • Quinaretic may raise your blood sugar. High blood sugar may make you feel confused, drowsy, or thirsty. It can also make you flush, breathe faster, or have a fruit-like breath odor. If these symptoms occur, tell your doctor right away.

  • Quinaretic may interfere with certain lab tests, including parathyroid function tests. Be sure your doctor and lab personnel know you are taking Quinaretic.

  • Lab tests, including liver and kidney function, blood pressure, complete blood cell counts, and blood electrolytes, may be performed while you take Quinaretic. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Quinaretic with caution in the ELDERLY; they may be more sensitive to its effects.

  • Quinaretic should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: Quinaretic may cause birth defects and fetal or newborn death if you take it while you are pregnant. Do not become pregnant while you take it. If you think you may be pregnant, contact your doctor right away. Quinaretic is found in breast milk. Do not breast-feed while you are taking Quinaretic.


Possible side effects of Quinaretic:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; dizziness or light-headedness; fatigue; headache; nausea; persistent dry cough; tiredness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty swallowing or breathing; tightness in the chest; swelling of the hands, mouth, face, lips, throat, or tongue; unusual hoarseness); chest pain; darkening of urine; decrease in the amount of urine; drowsiness; dry mouth; eye pain; fainting; fast, slow, or irregular heartbeat; muscle pain, weakness, or cramping; numbness of arm or leg; restlessness; severe or persistent dizziness or light-headedness; severe or persistent nausea, vomiting, or diarrhea; shortness of breath; slurred speech; stomach pain (with or without nausea or vomiting); sudden, severe headache or vomiting; symptoms of infection (eg, chills, fever, sore throat); symptoms of low blood sodium levels (eg, confusion, mental or mood changes, seizures, sluggishness); unusual bruising or bleeding; unusual joint pain; unusual thirst; unusual tiredness or weakness; unusual weight gain; vision changes (eg, decreased vision clearness); yellowing of the skin or eyes.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Quinaretic side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include fainting; severe dizziness or light-headedness; symptoms of blood electrolyte problems (eg, confusion; irregular heartbeat; mental or mood changes; muscle pain, weakness, or cramping; seizures; sluggishness); symptoms of dehydration (eg, dry mouth or eyes; decrease in the amount of urine; fast heartbeat; unusual thirst, tiredness, or weakness).


Proper storage of Quinaretic:

Store Quinaretic at room temperature, between 68 and 77 degrees F (20 and 25 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Quinaretic out of the reach of children and away from pets.


General information:


  • If you have any questions about Quinaretic, please talk with your doctor, pharmacist, or other health care provider.

  • Quinaretic is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Quinaretic. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Quinaretic resources


  • Quinaretic Side Effects (in more detail)
  • Quinaretic Use in Pregnancy & Breastfeeding
  • Drug Images
  • Quinaretic Drug Interactions
  • Quinaretic Support Group
  • 0 Reviews for Quinaretic - Add your own review/rating


  • Quinaretic Prescribing Information (FDA)

  • Accuretic Prescribing Information (FDA)

  • Accuretic Concise Consumer Information (Cerner Multum)



Compare Quinaretic with other medications


  • High Blood Pressure

Keratoconjunctivitis Medications


Definition of Keratoconjunctivitis: Inflammation of the cornea and conjunctiva.

Drugs associated with Keratoconjunctivitis

The following drugs and medications are in some way related to, or used in the treatment of Keratoconjunctivitis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.





Drug List:

Wednesday, 3 October 2012

Xeomin



botulinum toxin type a

Dosage Form: injection, powder, lyophilized, for solution
FULL PRESCRIBING INFORMATION
WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of Xeomin and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses [see Warnings and Precautions (5.1)].




Indications and Usage for Xeomin



Cervical Dystonia


Xeomin (incobotulinumtoxinA) is indicated for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients.



Blepharospasm


Xeomin (incobotulinumtoxinA) is indicated for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox).



Glabellar Lines


 Xeomin (incobotulinumtoxinA) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.



Xeomin Dosage and Administration


The potency Units of Xeomin (incobotulinumtoxinA) for injection are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of Xeomin cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method [see Warnings and Precautions (5.2) and Description (11)].



Cervical Dystonia


The recommended initial total dose of Xeomin for cervical dystonia is 120 Units. In a placebo-controlled trial utilizing initial Xeomin doses of 120 Units and 240 Units, no meaningful difference in effectiveness was demonstrated between the doses [see Clinical Studies (14.1)]. In previously treated patients, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the Xeomin dose.


In the treatment of cervical dystonia, Xeomin is usually injected into the sternocleidomastoid, levator scapulae, splenius capitis, scalenus, and/or the trapezius muscle(s). This list is not exhaustive, as any of the muscles responsible for controlling head position may require treatment [see Clinical Studies (14.1)]. The dose and number of injection sites in each treated muscle should be individualized based on the number and location of the muscle(s) to be treated, the degree of spasticity/dystonia, muscle mass, body weight, and response to any previous botulinum toxin injections.


The frequency of Xeomin repeat treatments should be determined by clinical response, but should generally be no more frequent than every 12 weeks [see Clinical Studies (14.1)].



Blepharospasm


The recommended initial total dose of Xeomin should be the same dose as the patient's previous treatment of onabotulinumtoxinA (Botox), although responses to Xeomin and onabotulinumtoxinA (Botox) may differ in individual patients. In a placebo-controlled trial in which patients were dosed with the same number of Units as they had received previously with onabotulinumtoxinA (Botox), the mean dose per eye was about 33 Units (range 10-50 Units), and the mean number of injections per eye was 6. The maximum dose per eye in the controlled trials was 50 Units, with a range of 10-50 Units. In the controlled trial, few patients received a total dose of greater than 75 Units.


If the previous dose of Botox is not known, the initial dose of Xeomin should be between 1.25-2.5 Units/injection site.


The total initial dose of Xeomin in both eyes should not exceed 70 Units (35 Units/eye).


The number and location of injection sites should be based on the severity of blepharospasm, and previous dose and response to onabotulinumtoxinA (Botox) injections. Subsequent dosing should be tailored to the individual patient, based on response, up to a maximum dose of 35 Units per eye [see Clinical Studies 14.2]. Xeomin dosing has not been established in patients with blepharospasm who have not been previously treated with onabotulinumtoxinA (Botox).


The frequency of Xeomin repeat treatments should be determined by clinical response but should generally be no more frequent than every 12 weeks [see Clinical Studies (14.2)].



Glabellar Lines


The total recommended Xeomin dose is 20 Units per treatment session divided into five equal intramuscular injections of 4 Units each. The five injection sites are: two injections in each corrugator muscle and one injection in the procerus muscle.


Retreatment with Xeomin should be administered no more frequently than every three months.





Figure 1: Injection Sites for Glabellar Lines

Special Populations


The safety and effectiveness of Xeomin in the treatment of cervical dystonia, blepharospasm, and glabellar lines in patients below 18 years of age have not been assessed [see Warnings and Precautions (5.1)].



Preparation and Reconstitution Technique


Prior to injection, reconstitute each vial of Xeomin with sterile, preservative-free 0.9% Sodium Chloride Injection, USP. Draw up an appropriate amount of preservative-free 0.9% Sodium Chloride Injection, USP into a syringe (see Table 1). Clean the exposed portion of the rubber stopper of the vial with alcohol (70%) prior to insertion of the needle. Gently inject the saline solution into the vial. If the vacuum does not pull the solvent into the vial, then Xeomin must be discarded. Gently mix Xeomin with the saline by rotating the vial. Reconstituted Xeomin is a clear, colorless solution free of particulate matter. Xeomin should not be used if the reconstituted solution has a cloudy appearance or contains floccular or particulate matter.


Diluent volumes for reconstitution of Xeomin are indicated in Table 1.


































Table 1: Diluent Volumes for Reconstitution of Xeomin
Volume of Preservative-free 0.9% Sodium Chloride Injection, USP50 Unit Vial:

Resulting dose in Units per 0.1 mL
100 Unit Vial:

Resulting dose in Units per 0.1 mL
0.25 mL20 Units-
0.5 mL10 Units20 Units
1 mL5 Units10 Units
1.25 mL4 Units8 Units
2 mL2.5 Units5 Units
2.5 mL2 Units4 Units
4 mL1.25 Units2.5 Units
5 mL1 Unit2 Units
8 mL-1.25 Units

Reconstituted Xeomin solution should be administered within 24 hours after dilution. During this time period, reconstituted Xeomin should be stored in a refrigerator 2-8°C (36-46°F) [see How Supplied/Storage and Handling (16.2)].



Administration


Reconstituted Xeomin is intended for intramuscular injection only. After reconstitution, Xeomin should be used for only one injection session and for only one patient.


If proposed injection sites are marked with a pen, the product must not be injected through the pen marks; otherwise a permanent tattooing effect may occur.


The number of injection sites is dependent upon the size of the muscle to be treated and the volume of reconstituted Xeomin injected.


Xeomin should be injected carefully when injected at sites close to sensitive structures, such as the carotid artery, lung apices and esophagus. Before administering Xeomin, the physician should be familiar with the patient's anatomy and any anatomic alterations, e.g., due to prior surgical procedures.



Cervical Dystonia


A suitable sterile needle (e.g., 26-gauge (0.45 mm diameter), 37 mm length for superficial muscles; or 22-gauge (0.70 mm diameter), 75 mm length for injections into deeper muscles) should be used in the administration in the treatment of cervical dystonia.


Localization of the involved muscles with electromyographic guidance or nerve stimulation techniques may be useful.



Blepharospasm


A suitable sterile needle (e.g., 26-gauge (0.45 mm diameter), 37 mm length for superficial muscles; or 22-gauge (0.70 mm diameter), 75 mm length for injections into deeper muscles) should be used in the administration in the treatment of blepharospasm.



Glabellar Lines


A suitable sterile needle 30-33 gauge (0.3-0.2 mm diameter), 13 mm length should be used in the administration in the treatment of glabellar lines.



Monitoring to Assess Effectiveness


The median first onset of Xeomin effect occurs within seven days after injection. The typical duration of effect of each treatment is up to 3 months; however, the effect may last significantly longer, or shorter, in individual patients.



Dosage Forms and Strengths


Single-use, sterile 50 Units or 100 Units lyophilized powder for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection, USP, prior to injection.



Contraindications



Hypersensitivity


Use in patients with a known hypersensitivity to the active substance botulinum neurotoxin type A, or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction. Xeomin is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation [see Warnings and Precautions (5.3) and Description (11)].



Infection at Injection Site


Use in patients with an infection at the injection site could lead to severe local or disseminated infection. Xeomin is contraindicated in the presence of infection at the proposed injection site(s).



Warnings and Precautions



Spread of Toxin Effect


Postmarketing safety data from Xeomin and other approved botulinum toxins suggest that botulinum toxin effects may, in some cases, be observed beyond the site of local injection. The symptoms are consistent with the mechanism of action of botulinum toxin and may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death related to the spread of toxin effects. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can occur in adults treated for spasticity and other conditions, and particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, symptoms consistent with spread of toxin effect have been reported at doses comparable to or lower than doses used to treat cervical dystonia.


Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.



Lack of Interchangeability between Botulinum Toxin Products


The potency Units of Xeomin are specific to the preparation and assay method utilized. They are not interchangeable with the other preparations of botulinum toxin products and, therefore, Units of biological activity of Xeomin cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method [see Description (11)].



Hypersensitivity Reactions


Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of Xeomin should be discontinued and appropriate medical therapy immediately instituted.



Dysphagia and Breathing Difficulties in Treatment of Cervical Dystonia


Treatment with Xeomin and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [See Warnings and Precautions (5.1)].


Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.


Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products.


Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles have been reported to be at greater risk of dysphagia. In general, limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.


Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin [See Warnings and Precautions (5.1) and Adverse Reactions (6.1)].



Pre-existing Neuromuscular Disorders and other Special Populations


Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of Xeomin [See Adverse Reactions (6.1)].



Corneal Exposure, Corneal Ulceration, and Ectropion in Patients Treated with Xeomin for Blepharospasm


Reduced blinking from injection of botulinum toxin products in the orbicularis muscle can lead to corneal exposure, persistent epithelial defect and corneal ulceration, especially in patients with VII nerve disorders. Careful testing of corneal sensation in eyes previously operated upon, avoidance of injection into the lower lid area to avoid ectropion, and vigorous treatment of any epithelial defect should be employed. This may require protective drops, ointment, therapeutic soft contact lenses, or closure of the eye by patching or other means. Because of its anticholinergic effects, Xeomin should be used with caution in patients at risk of developing narrow angle glaucoma. To prevent ectropion, botulinum toxin products should not be injected into the medial lower eyelid area.


Ecchymosis easily occurs in the soft tissues of the eyelid. Immediate gentle pressure at the injection site can limit that risk.



Risk of Ptosis in Patients Treated with Xeomin for Glabellar Lines


Do not exceed the recommended dosage and frequency of administration of Xeomin.


In order to reduce the complication of ptosis the following steps should be taken:


  • Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes.

  • Corrugator injections should be placed at least 1 cm above the bony supraorbital ridge.


Human Albumin and Transmission of Viral Diseases


This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been reported for albumin.



Adverse Reactions


The following adverse reactions to Xeomin are discussed in greater detail in other sections of the labeling:


  • Hypersensitivity [see Contraindications (4) and Warnings and Precautions (5.3)]

  • Dysphagia and Breathing Difficulties in Treatment of cervical dystonia [see Warnings and Precautions (5.4)]

  • Spread of Effects from Toxin [see Warnings and Precautions (5.1)]


Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in practice.



Cervical Dystonia


The data described below reflect exposure to a single intramuscular dose of Xeomin in a placebo-controlled, Phase 3 trial in patients with cervical dystonia [see Clinical Studies (14.1)]. In this study, 159 patients received Xeomin (78 were randomized to receive a total dose of 120 Units, and 81 were randomized to receive a total dose of 240 Units). Xeomin-treated patients were 18 to 79 years old (mean 53 years), and were predominantly female (66%) and Caucasian (91%). At study baseline, approximately 25% had mild, 50% had moderate, and 25% had severe cervical dystonia. Approximately 61% of Xeomin-treated patients had previously received another botulinum toxin type A product. Common adverse events (≥5% in any Xeomin treatment group) observed in patients who received Xeomin (120 Units or 240 Units) included dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.


























































Table 2: Most Common TEAEs (≥5%) and Greater than Placebo: Double-Blind Phase of Clinical Trial
Double-Blind Phase
System Organ Class

Preferred Term
Xeomin 120 Units

(N=77)
Xeomin 240 Units

(N=82)
Placebo

(N=74)
Any TEAEs57%55%42%
Musculoskeletal and connective tissue disorders23%32%11%
  Neck pain7%15%4%
  Muscular weakness7%11%1%
  Musculoskeletal pain7%4%1%
Gastrointestinal disorders18%24%4%
  Dysphagia13%18%3%
Nervous system disorders16%17%7%
General disorders and administration site conditions16%11%11%
  Injection site pain9%4%7%
Infections and infestations14%13%11%
Respiratory, thoracic and mediastinal disorders13%10%3%

Blepharospasm


In the placebo-controlled Phase 3 trial in patients with blepharospasm previously treated with onabotulinumtoxinA (Botox) [see Clinical Studies (14.2)], 74 patients received Xeomin at a mean dose of approximately 33 Units per eye (minimum 10 Units, maximum 50 Units). Xeomin-treated patients were 22 to 79 years of age (mean 62 years), predominantly female (65%), Caucasian (79%), and had a mean time since diagnosis of approximately 5 years.


The adverse events occurring in ≥5% of Xeomin-treated patients and greater than placebo in the Phase 3 study were eyelid ptosis, dry eye, dry mouth, diarrhea, headache, visual impairment, dyspnea, nasopharyngitis, and respiratory tract infection. No serious adverse events occurred in patients who received Xeomin; one placebo-treated patient experienced a serious adverse event (dyspnea).


























































Table 3: Most Common TEAEs (≥5%) and Greater than Placebo: Double-Blind Phase of Clinical Trial
Double-Blind Phase
System Organ Class

  Preferred Term
Xeomin

(N=74)
Placebo

(N=34)

*

including vision blurred

Subjects with TEAEs70%62%
Eye disorders38%21%
  Eyelid ptosis19%9%
  Dry eye16%12%
  Visual impairment*12%6%
Gastrointestinal disorders30%15%
  Dry mouth16%3%
  Diarrhoea8%-
Infections and infestations20%15%
  Nasopharyngitis5%3%
Respiratory tract infection5%3%
Nervous system disorders14%9%
  Headache7%3%
General disorders and administration site conditions11%9%
Respiratory, thoracic and mediastinal disorders11%3%
  Dyspnoea5%3%

Glabellar Lines


In three placebo-controlled trials in 803 subjects with glabellar lines, 535 subjects received a single dose of 20 Units Xeomin and 268 subjects received placebo. Xeomin treated subjects were 24 to 74 years old, and were predominantly female (88%). The most frequent adverse reactions in Xeomin treated subjects were: headache 29 (5.4%), facial paresis 4 (0.7%), injection site hematoma 3 (0.6%) and eyelid edema 2 (0.4%). Four serious adverse events occurred in two placebo-treated subjects. Six Xeomin treated subjects experienced six serious adverse events. All serious adverse events were assessed as unrelated to study drug.


The adverse reactions below reflect exposure to Xeomin with glabellar lines in placebo-controlled studies. Adverse reactions are adverse events in which there is some basis to believe there is a causal relationship between the drug and the occurrence of the adverse event.


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

















































Table 4: Adverse Reactions in Placebo-Controlled Trials
Adverse reactionsXeomin

(N=535) (%)
Placebo

(N=268) (%)
Nervous system disorders33 (6.1)6 (2.2)
Headache129 (5.4)6 (2.2)
Facial paresis (brow ptosis)4 (0.7)0
General disorders and administration site conditions5 (0.9)2 (0.7)
Injection site hematoma3 (0.6)0
Injection site pain1 (0.2)0
Facial pain1 (0.2)0
Injection site swelling01 (0.4)
Sensation of pressure01 (0.4)
Eye disorders5 (0.9)0
Eyelid edema
2 (0.4)0
Blepharospasm1 (0.2)0
Eye disorder1(0.2)0
Eyelid ptosis1(0.2)0

In open label, multiple dose trials, adverse reactions were reported for 105 of the 800 subjects (13.1%). Headache was the most common adverse reaction, reported for 57 subjects (7.1%), followed by injection site hematoma in 8 subjects (1.0%). Adverse reactions reported in less than 1% of subjects were: facial paresis (brow ptosis), muscle disorder (elevation of eyebrow), injection site pain, and eyelid edema.



Immunogenicity


As with all therapeutic proteins, there is a potential for immunogenicity.


The incidence of antibody formation is highly dependent on the sensitivity and specificity of the assay. In addition, the observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies across products in this class may be misleading.



Postmarketing Experience


The following adverse reactions have been reported during post-approval use with Xeomin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: eye swelling, eyelid edema, dysphagia, nausea, injection site pain, injection site reaction, allergic dermatitis, localized allergic reactions like swelling, edema, erythema, pruritus or rash, herpes zoster, muscular weakness, muscle spasm, dysarthria, myalgia and hypersensitivity.



Drug Interactions


No formal drug interaction studies have been conducted with Xeomin.


Coadministration of Xeomin and aminoglycoside antibiotics or other agents interfering with neuromuscular transmission, e.g., tubocurarine-type muscle relaxants, should only be performed with caution as these agents may potentiate the effect of the toxin.


Use of anticholinergic drugs after administration of Xeomin may potentiate systemic anticholinergic effects.


The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of Xeomin.



USE IN SPECIFIC POPULATIONS



Pregnancy



Pregnancy Category C:


There are no adequate and well-controlled studies in pregnant women. Xeomin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Xeomin was embryotoxic in rats and increased abortions in rabbits when given at doses higher than the maximum recommended human dose (MRHD) for cervical dystonia (120 Units) on a body weight basis.


When Xeomin was administered intramuscularly to pregnant rats during organogenesis (3, 10, or 30 Units/kg on gestational days [GDs] 6, 12, and 19; or 7 Units/kg on GDs 6 to 19; or 2, 6, or 18 Units/kg on GDs 6, 9, 12, 16, and 19), decreases in fetal body weight and skeletal ossification were observed at doses that were also maternally toxic. The no-effect level for embryotoxicity in rats was 6 Units/kg (3 times the MRHD for cervical dystonia on a body weight basis). Intramuscular administration to pregnant rabbits during organogenesis (1.25, 2.5, or 5.0 Units/kg on GDs 6, 18, and 28) resulted in an increased rate of abortion at the highest dose, which was also maternally toxic. In rabbits, the no-effect level for increased abortion was 2.5 Units/kg (similar to the MRHD for cervical dystonia on a body weight basis).



Nursing Mothers


It is not known whether botulinum toxin type A is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Xeomin is administered to a nursing woman.



Pediatric Use


Safety and effectiveness of Xeomin in patients less than 18 years of age have not been established [see Warnings and Precautions (5.1)].



Geriatric Use



Cervical Dystonia


In the Phase 3 study in cervical dystonia [see Clinical Studies (14.1)], 29 patients were older than 65 years of age, including 19 patients who received Xeomin and 10 patients who received placebo. Of these, ten (53%) Xeomin-treated patients and four (40%) placebo-treated patients experienced an adverse event. For patients over 65 years of age treated with Xeomin, the most common adverse events were dysphagia (4 patients, 21%) and asthenia (2 patients, 11%). One Xeomin-treated patient (5%) experienced severe dizziness.



Blepharospasm


In the Phase 3 study in blepharospasm [see Clinical Studies (14.2)], 41 patients were older than 65 years of age, including 29 of 75 patients (39%) who received Xeomin and 12 of 34 patients (35%) who received placebo. Of these patients, 22 of 29 (76%) Xeomin-treated patients, compared with 7 of 12 (58%) placebo-treated patients, experienced an adverse event. One Xeomin-treated patient experienced severe dysphagia.



Glabellar Lines


There are limited clinical data with Xeomin in subjects over 65 years of age and over in clinical studies with glabellar lines. Of the total number of subjects in the placebo-controlled clinical studies GL1 and GL2, 21 (4%) subjects were 65 and over. Efficacy was observed in 20% (3/15) of Xeomin subjects 65 years and over. For the entire safety database of geriatric subjects, there was no increase in the incidence of adverse events related to treatment with Xeomin.



Overdosage


Excessive doses of Xeomin may be expected to produce neuromuscular weakness with a variety of symptoms. Respiratory support may be required where excessive doses cause paralysis of the respiratory muscles. In the event of overdose, the patient should be medically monitored for symptoms of excessive muscle weakness or muscle paralysis [See Warnings and Precautions (5.1, 5.4)]. Symptomatic treatment may be necessary.


Symptoms of overdose are not likely to be present immediately following injection. Should accidental injection or oral ingestion occur, the person should be medically supervised for several weeks for signs and symptoms of excessive muscle weakness or paralysis.


There is no significant information regarding overdose from clinical studies in cervical dystonia and blepharospasm.


In the event of overdose, antitoxin raised against botulinum toxin is available from the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. However, the antitoxin will not reverse any botulinum toxin-induced effects already apparent by the time of antitoxin administration. In the event of suspected or actual cases of botulinum toxin poisoning, please contact your local or state Health Department to process a request for antitoxin through the CDC. If you do not receive a response within 30 minutes, please contact the CDC directly at 770-488-7100. More information can be obtained at http://www.cdc.gov/ncidod/srp/drugs/formulary.html#1a.



Xeomin Description


The active ingredient of Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A. The botulinum toxin complex is purified from the culture supernatant and then the active ingredient is separated from the proteins (hemagglutinins and non-hemagglutinins) through a series of steps yielding the active neurotoxin with molecular weight of 150 kDa, without accessory proteins. Xeomin is a sterile white to off-white lyophilized powder intended for intramuscular injection after reconstitution with preservative-free 0.9% Saline for Injection. One vial of Xeomin contains 50 or 100 Units of incobotulinumtoxinA, 1 mg of human albumin, and 4.7 mg sucrose. One Unit corresponds to the mouse median lethal dose (LD50) when the reconstituted product is injected intraperitoneally into mice under defined conditions. The method for conducting the assay is specific to Xeomin, Units of biological activity of Xeomin cannot be converted into Units of any other botulinum toxin assessed with other specific assays.



Xeomin - Clinical Pharmacology



Mechanism of Action


Xeomin blocks cholinergic transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine. Impulse transmission is re-established by the formation of new nerve endings.



Pharmacodynamics


In patients, recovery from paralysis after intramuscular injection normally occurs within 3-4 months as nerve terminals sprout and reconnect with the muscle endplate.



Pharmacokinetics


General characteristics of the active substance:


Using currently available analytical technology, it is not possible to detect Xeomin in the peripheral blood following intramuscular injection at the recommended doses.



Nonclinical Toxicology



Carcinogenesis, Mutagenesis, Impairment of Fertility



Carcinogenesis


Studies to evaluate the carcinogenic potential of Xeomin have not been conducted.



Mutagenesis


Genotoxicity studies have not been conducted for Xeomin.



Impairment of Fertility


In a fertility and early embryonic development study in rabbits, males and females were dosed with Xeomin (1.25, 2.5, or 3.5 Units/kg) intramuscularly every two weeks for 5 and 3 doses, respectively, beginning 2 weeks prior to mating. No effects on mating or fertility were observed . The highest dose tested is approximately twice the maximum recommended human dose for cervical dystonia (120 Units) on a body weight basis.



Clinical Studies



Cervical Dystonia


Xeomin has been investigated in a Phase 3, randomized, double-blind, placebo-controlled, multi-center trial in a total of 233 patients with cervical dystonia. Patients had a clinical diagnosis of predominantly rotational cervical dystonia, with baseline Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) total score ≥20, TWSTRS severity score ≥10, TWSTRS disability score ≥3, and TWSTRS pain score ≥1. For patients who had previously received a botulinum toxin treatment for cervical dystonia, the trial required that ≥10 weeks had passed since the most recent botulinum toxin administration. Patients with swallowing disorders or any significant neuromuscular disease that might interfere with the study were excluded from enrollment. Patients were randomized (1:1:1) to receive a single administration of Xeomin 240 Units (n=81), Xeomin 120 Units (n=78), or placebo (n=74). Each patient received a single administration of 4.8 mL of reconstituted study agent (Xeomin 240 Units, Xeomin 120 Units, or placebo). The investigator at each site decided which muscles would receive injections of the study agent, the number of injection sites, and the volume at each site. The muscles most frequently injected were the splenius capitis/semispinalis, trapezius, sternocleidomastoid, scalene, and levator scapulae muscles. Table 5 indicates the average Xeomin dose, and percentage of total dose, injected into specific muscles in the pivotal clinical trial.





























Table 5: Xeomin 120 Units Initial Dose (Units and % of the Total Dose) by Unilateral Muscle Injected During Double Blind Pivotal Phase 3 Study
Xeomin Dose Injected
Number of Patients Injected Per MuscleMedian

Xeomin Units
75th percentile

Xeomin Units
Sternocleidomastoid632535
Splenius capitis/ Semispinalis capitis784863
Trapezius552538
Levator scapulae492525
Scalenus (medius and anterior)272025

Most patients received a total of 2-10 injections into the selected muscles. Patients were assessed by telephone at one week post-injection, during clinic visits at Weeks 4 and 8, and then by telephone assessments or clinic visits every two weeks up to Week 20.


The mean age of the study patients was 53 years, and 66% of the patients were women. At study baseline, 61% of patients had previously received a botulinum toxin as treatment for cervical dystonia. The study was completed by 94% of study patients. Three patients discontinued the study prematurely due to adverse events: two patients in the 240 Unit group experienced musculoskeletal pain and muscle weakness, and one patient in the 120 Unit group experienced nausea and dizziness.


The primary efficacy endpoint was the change in the TWSTRS total score from baseline to Week 4 post-injection, in the intent-to-treat (ITT) population, with missing values replaced by the patient's baseline value. In the ITT population, the difference between the Xeomin 240 Unit group and the placebo group in the change of the TWSTRS total score from baseline to Week 4 was -9.0 points, 95% confidence interval (CI) -12.0; -5.9 points; the difference between the Xeomin 120 Unit group and the placebo group in the change of the TWSTRS total score from baseline to Week 4 was -7.5 points, 95% CI -10.4; -4.6 points.


Figure 2 illustrates the cumulative percentage of patients from each of the three treatment groups who had attained the specified change in TWSTRS Score from baseline versus 4 weeks post-injection. Three change scores have been identified for illu

Tuesday, 2 October 2012

phenylephrine Nasal



fen-il-EF-rin


Commonly used brand name(s)

In the U.S.


  • Neo-Synephrine

  • Nostril

  • Pretz-D

  • Rhinall

  • Tur-Bi-Cal

  • Vicks Sinex

Available Dosage Forms:


  • Solution

  • Gel/Jelly

  • Spray

Therapeutic Class: Decongestant


Pharmacologic Class: Sympathomimetic


Chemical Class: Alkylarylamine


Uses For phenylephrine


Phenylephrine is used for the temporary relief of congestion or stuffiness in the nose caused by hay fever or other allergies, colds, or sinus trouble. It may also be used in ear infections to relieve congestion.


phenylephrine may also be used for other conditions as determined by your doctor.


phenylephrine is available without a prescription.


Do not give any over-the-counter (OTC) cough and cold medicine to a baby or child under 4 years of age. Using these medicines in very young children might cause serious or possibly life-threatening side effects .


Before Using phenylephrine


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For phenylephrine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to phenylephrine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Children may be especially sensitive to the effects of nasal phenylephrine. This may increase the chance of side effects during treatment.


Do not give any over-the-counter (OTC) cough and cold medicine to a baby or child under 4 years of age. Using these medicines in very young children might cause serious or possibly life-threatening side effects .


Geriatric


Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of nasal phenylephrine in the elderly with use in other age groups.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking phenylephrine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using phenylephrine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Rasagiline

  • Selegiline

Using phenylephrine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Amitriptyline

  • Amoxapine

  • Clomipramine

  • Desipramine

  • Dothiepin

  • Doxepin

  • Imipramine

  • Lofepramine

  • Nortriptyline

  • Opipramol

  • Protriptyline

  • Trimipramine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of phenylephrine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Type 2 diabetes mellitus or

  • Heart or blood vessel disease or

  • High blood pressure or

  • Overactive thyroid—Nasal phenylephrine may make the condition worse

Proper Use of phenylephrine


To use the nose drops:


  • Blow your nose gently. Tilt the head back while standing or sitting up, or lie down on a bed and hang head over the side. Place the drops into each nostril and keep the head tilted back for a few minutes to allow the medicine to spread throughout the nose.

  • Rinse the dropper with hot water and dry with a clean tissue. Replace the cap right after use.

  • To avoid spreading the infection, do not use the container for more than one person.

To use the nose spray:


  • Blow your nose gently. With the head upright, spray the medicine into each nostril. Sniff briskly while squeezing the bottle quickly and firmly. For best results, spray once or twice into each nostril and wait 3 to 5 minutes to allow the medicine to work. Then, blow your nose gently and thoroughly. Repeat until the complete dose is used.

  • Rinse the tip of the spray bottle with hot water, taking care not to suck water into the bottle, and dry with a clean tissue. Replace the cap right after use.

  • To avoid spreading the infection, do not use the container for more than one person.

To use the nose jelly:


  • Blow your nose gently. Wash your hands before applying the medicine. With your finger, place a small amount of jelly (about the size of a pea) up each nostril. Sniff it well back into the nose.

  • Wipe the tip of the tube with a clean, damp tissue and replace the cap right after use.

Use phenylephrine only as directed. Do not use more of it, do not use it more often, and do not use it for longer than 3 days without first checking with your doctor. To do so may make your runny or stuffy nose worse and may also increase the chance of side effects.


Dosing


The dose of phenylephrine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of phenylephrine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For stuffy nose:
    • For nose jelly dosage form:
      • Adults—Use a small amount in the nose every three or four hours as needed.

      • Children—Use is not recommended.


    • For nose drops dosage form:
      • Adults and children 12 years of age and older—Use two or three drops of a 0.25 to 0.5% solution in the nose every four hours as needed.

      • Children 6 to 12 years of age—Use two or three drops of a 0.25% solution in the nose every four hours as needed.

      • Children 4 to 6 years of age—Use two or three drops of a 0.125 or 0.16% solution in the nose every four hours as needed.

      • Children and infants up to 4 years of age—Use is not recommended .


    • For nose spray dosage form:
      • Adults and children 12 years of age and older—Use two or three sprays of a 0.25 to 0.5% solution in the nose every four hours as needed.

      • Children 6 to 12 years of age—Use two or three sprays of a 0.25% solution in the nose every four hours as needed.

      • Children 4 to 6 years of age—Use and dose must be determined by your doctor.

      • Children and infants up to 4 years of age—Use is not recommended .



Missed Dose


If you miss a dose of phenylephrine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


phenylephrine Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Symptoms of too much medicine being absorbed into the body

Note: The above side effects are more likely to occur in children because there is a greater chance that too much of phenylephrine may be absorbed into the body.


  • Fast, irregular, or pounding heartbeat

  • headache or dizziness

  • increased sweating

  • nervousness

  • paleness

  • trembling

  • trouble in sleeping

  • Increase in runny or stuffy nose

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


  • Burning, dryness, or stinging of inside of nose

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More phenylephrine Nasal resources


  • Phenylephrine Nasal Use in Pregnancy & Breastfeeding
  • Phenylephrine Nasal Drug Interactions
  • Phenylephrine Nasal Support Group
  • 4 Reviews for Phenylephrine Nasal - Add your own review/rating


  • phenylephrine nasal Concise Consumer Information (Cerner Multum)

  • Alconefrin-12 Concise Consumer Information (Cerner Multum)

  • Rhinall Solution MedFacts Consumer Leaflet (Wolters Kluwer)



Compare phenylephrine Nasal with other medications


  • Nasal Congestion

Fluoxetine




Generic Name: Fluoxetine hydrochloride

Dosage Form: tablet, film coated
FULL PRESCRIBING INFORMATION
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Fluoxetine tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Fluoxetine is approved for use in pediatric patients with MDD and Obsessive Compulsive Disorder (OCD) [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].




Indications and Usage for Fluoxetine



Major Depressive Disorder


Fluoxetine is indicated for the treatment of Major Depressive Disorder (MDD) [see Clinical Studies (14.1)]. The efficacy of Fluoxetine in MDD was established in one 5 week trial, three 6 week trials, and one maintenance study in adults. The efficacy of Fluoxetine was also established in two 8 to 9 week trials in pediatric patients aged 8 to 18 years; doses greater than 20 mg/day have not been studied in pediatric patients with MDD.


The usefulness of the drug in adult and pediatric patients receiving Fluoxetine for extended periods should periodically be re-evaluated [see Dosage and Administration (2.1)].



Obsessive Compulsive Disorder


Fluoxetine is indicated for the treatment of Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2)]. The efficacy of Fluoxetine in OCD was demonstrated in two 13 week trials in adults and one 13 week trial in pediatric patients aged 7 to 17 years.


The effectiveness of Fluoxetine in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use Fluoxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.2)].



Bulimia Nervosa


Fluoxetine is indicated for the treatment of moderate to severe Bulimia Nervosa [see Clinical Studies (14.3)]. The efficacy of Fluoxetine in Bulimia was demonstrated in two 8 week trials and one 16 week trial in adults.


The physician who elects to use Fluoxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.3)].



Panic Disorder


Fluoxetine is indicated for the treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4)]. The efficacy of Fluoxetine in Panic Disorder was demonstrated in two 12 week trials in adults.


The effectiveness of Fluoxetine in long-term use, i.e., for more than 12 weeks, has not been established in placebo-controlled trials. Therefore, the physician who elects to use Fluoxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.4)].



Fluoxetine Dosage and Administration


This product is only available in a 60 mg dosage form. A 30 mg dose may be achieved with one-half of the scored tablet. Use of this product requires initial titration with another Fluoxetine product according to the dosing guidelines indicated below.



Major Depressive Disorder


Initial Treatment


Adult — In controlled trials used to support the efficacy of Fluoxetine, patients were administered morning doses ranging from 20 to 80 mg/day. Studies comparing Fluoxetine 20, 40, and 60 mg/day to placebo indicate that 20 mg/day is sufficient to obtain a satisfactory response in MDD in most cases. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. A dose increase may be considered after several weeks if insufficient clinical improvement is observed. Doses above 20 mg/day may be administered on a once daily (morning) or twice daily schedule (i.e., morning and noon) and should not exceed a maximum dose of 80 mg/day.


Pediatric (children and adolescents) — In the short-term (8 to 9 week) controlled clinical trials of Fluoxetine supporting its effectiveness in the treatment of MDD, patients were administered Fluoxetine doses of 10 to 20 mg/day [see Clinical Studies (14.1)]. Treatment should be initiated with a dose of 10 or 20 mg/day. After 1 week at 10 mg/day, the dose should be increased to 20 mg/day. However, due to higher plasma levels in lower weight children, the starting and target dose in this group may be 10 mg/day. A dose increase to 20 mg/day may be considered after several weeks if insufficient clinical improvement is observed. This product is only available in a 60 mg dosage form. Administration of doses with demonstrated efficacy of Fluoxetine 10 to 20 mg/day in pediatric MDD requires the use of another formulation.


All patients — As with other drugs effective in the treatment of MDD, the full effect may be delayed until 4 weeks of treatment or longer.


Maintenance/Continuation/Extended Treatment — It is generally agreed that acute episodes of MDD require several months or longer of sustained pharmacologic therapy. Whether the dose needed to induce remission is identical to the dose needed to maintain and/or sustain euthymia is unknown.


Daily Dosing — Systematic evaluation of Fluoxetine in adult patients has shown that its efficacy in MDD is maintained for periods of up to 38 weeks following 12 weeks of open-label acute treatment (50 weeks total) at a dose of 20 mg/day [see Clinical Studies (14.1)].


Switching Patients to a Tricyclic Antidepressant (TCA) — Dosage of a TCA may need to be reduced, and plasma TCA concentrations may need to be monitored temporarily when Fluoxetine is coadministered or has been recently discontinued [see Drug Interactions (7.8)].


Switching Patients to or From a Monoamine Oxidase Inhibitor (MAOI) — At least 14 days should elapse between discontinuation of an MAOI and initiation of therapy with Fluoxetine. In addition, at least 5 weeks, perhaps longer, should be allowed after stopping Fluoxetine before starting an MAOI [see Contraindications (4) and Drug Interactions (7.1)].



Obsessive Compulsive Disorder


Initial Treatment


Adults — In the controlled clinical trials of Fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered fixed daily doses of 20, 40, or 60 mg of Fluoxetine or placebo [see Clinical Studies (14.2)]. In one of these studies, no dose-response relationship for effectiveness was demonstrated. Consequently, a dose of 20 mg/day, administered in the morning, is recommended as the initial dose. Since there was a suggestion of a possible dose-response relationship for effectiveness in the second study, a dose increase may be considered after several weeks if insufficient clinical improvement is observed. The full therapeutic effect may be delayed until 5 weeks of treatment or longer.


Doses above 20 mg/day may be administered on a once daily (i.e., morning) or twice daily schedule (i.e., morning and noon). A dose range of 20 to 60 mg/day is recommended; however, doses of up to 80 mg/day have been well tolerated in open studies of OCD. The maximum Fluoxetine dose should not exceed 80 mg/day.


Pediatric (children and adolescents) — In the controlled clinical trial of Fluoxetine supporting its effectiveness in the treatment of OCD, patients were administered Fluoxetine doses in the range of 10 to 60 mg/day [see Clinical Studies (14.2)].


In adolescents and higher weight children, treatment should be initiated with a dose of 10 mg/day. After 2 weeks, the dose should be increased to 20 mg/day. Additional dose increases may be considered after several more weeks if insufficient clinical improvement is observed. A dose range of 20 to 60 mg/day is recommended.


In lower weight children, treatment should be initiated with a dose of 10 mg/day. Additional dose increases may be considered after several more weeks if insufficient clinical improvement is observed. A dose range of 20 to 30 mg/day is recommended. Experience with daily doses greater than 20 mg is very minimal, and there is no experience with doses greater than 60 mg.


Maintenance/Continuation Treatment — While there are no systematic studies that answer the question of how long to continue Fluoxetine, OCD is a chronic condition and it is reasonable to consider continuation for a responding patient. Although the efficacy of Fluoxetine after 13 weeks has not been documented in controlled trials, adult patients have been continued in therapy under double-blind conditions for up to an additional 6 months without loss of benefit. However, dosage adjustments should be made to maintain the patient on the lowest effective dosage, and patients should be periodically reassessed to determine the need for treatment.



Bulimia Nervosa


Initial Treatment — In the controlled clinical trials of Fluoxetine supporting its effectiveness in the treatment of Bulimia Nervosa, patients were administered fixed daily Fluoxetine doses of 20 or 60 mg, or placebo [see Clinical Studies (14.3)]. Only the 60 mg dose was statistically significantly superior to placebo in reducing the frequency of binge-eating and vomiting. Consequently, the recommended dose is 60 mg/day, administered in the morning. For some patients it may be advisable to titrate up to this target dose over several days. Fluoxetine doses above 60 mg/day have not been systematically studied in patients with bulimia.


Maintenance/Continuation Treatment — Systematic evaluation of continuing Fluoxetine 60 mg/day for periods of up to 52 weeks in patients with bulimia who have responded while taking Fluoxetine 60 mg/day during an 8 week acute treatment phase has demonstrated a benefit of such maintenance treatment [see Clinical Studies (14.3)]. Nevertheless, patients should be periodically reassessed to determine the need for maintenance treatment.



Panic Disorder


Initial Treatment — In the controlled clinical trials of Fluoxetine supporting its effectiveness in the treatment of Panic Disorder, patients were administered Fluoxetine doses in the range of 10 to 60 mg/day [see Clinical Studies (14.4)]. Treatment should be initiated with a dose of 10 mg/day. After one week, the dose should be increased to 20 mg/day. The most frequently administered dose in the 2 flexible-dose clinical trials was 20 mg/day. A dose increase may be considered after several weeks if no clinical improvement is observed. Fluoxetine doses above 60 mg/day have not been systematically evaluated in patients with Panic Disorder.


Maintenance/Continuation Treatment — While there are no systematic studies that answer the question of how long to continue Fluoxetine, panic disorder is a chronic condition and it is reasonable to consider continuation for a responding patient. Nevertheless, patients should be periodically reassessed to determine the need for continued treatment.



Dosing in Specific Populations


Treatment of Pregnant Women During the Third Trimester — When treating pregnant women with Fluoxetine during the third trimester, the physician should carefully consider the potential risks and potential benefits of treatment. Neonates exposed to SNRIs or SSRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. The physician may consider tapering Fluoxetine in the third trimester [see Use in Specific Populations (8.1)].


Geriatrics — A lower or less frequent dosage should be considered for the elderly [see Use in Specific Populations (8.5)].


Hepatic Impairment — As with many other medications, a lower or less frequent dosage should be used in patients with hepatic impairment [see Clinical Pharmacology (12.3) and Use in Specific Populations (8.6)].



Dosage Forms and Strengths


Fluoxetine tablets, USP 60 mg, are available as 60 mg (Fluoxetine base equivalent), film coated, functionally scored, capsule-shaped, white tablets debossed with “FL 60” on one side (“FL” above the score and “60” below the score).



Contraindications


The use of Fluoxetine is contraindicated with the following:


  • Monoamine Oxidase Inhibitors: Do not use with an MAOI or within 14 days of discontinuing an MAOI due to risk of drug interaction. At least 5 weeks should be allowed after stopping Fluoxetine before treatment with an MAOI [see Drug Interactions (7.1)]

  • Pimozide: Do not use with pimozide due to risk of QTc prolongation [see Drug Interactions (7.8)].

  • Thioridazine: Do not use with thioridazine due to QTc interval prolongation. Do not use thioridazine within 5 weeks of discontinuing Fluoxetine [see Drug Interactions (7.8)].

  • Known hypersensitivity to Fluoxetine: Do not use this product in patients with known hypersensitivity to Fluoxetine due to risk of anaphylactoid reactions, including bronchospasm, angioedema, laryngospasm, and urticaria [see Warnings and Precautions (5.3)].


Warnings and Precautions



Clinical Worsening and Suicide Risk


Patients with MDD, both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.


The pooled analyses of placebo-controlled trials in children and adolescents with MDD, OCD, or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug versus placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.


















Table 1. Suicidality per 1000 Patients Treated
Age Range          Drug-Placebo Difference in Number of Cases of Suicidality per 1000 Patients Treated
 Increases Compared to Placebo
<1814 additional cases
18–245 additional cases
Decreases Compared to Placebo   
25–641 fewer case
≥656 fewer cases

No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide.


It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.


All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.


The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for MDD as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.


Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient’s presenting symptoms.


If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Warnings and Precautions (5.13)].


Families and caregivers of patients being treated with antidepressants for MDD or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should include daily observation by families and caregivers. Prescriptions for Fluoxetine should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.


It should be noted that Fluoxetine is approved in the pediatric population only for MDD and OCD.



Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-Like Reactions


The development of a potentially life-threatening serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reactions have been reported with SNRIs and SSRIs alone, including Fluoxetine treatment, but particularly with concomitant use of serotonergic drugs (including triptans) with drugs which impair metabolism of serotonin (including MAOIs), or with antipsychotics or other dopamine antagonists. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Serotonin syndrome, in its most severe form can resemble neuroleptic malignant syndrome, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs, and mental status changes. Patients should be monitored for the emergence of serotonin syndrome or NMS-like signs and symptoms.


The concomitant use of Fluoxetine with MAOIs intended to treat depression is contraindicated [see Contraindications (4) and Drug Interactions (7.1)].


If concomitant treatment of Fluoxetine with a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases [see Drug Interactions (7.4)].


The concomitant use of Fluoxetine with serotonin precursors (such as tryptophan) is not recommended [see Drug Interactions (7.3)].


Treatment with Fluoxetine and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above reactions occur, and supportive symptomatic treatment should be initiated.



Allergic Reactions and Rash


In U.S. Fluoxetine clinical trials, 7% of 10,782 patients developed various types of rashes and/or urticaria. Among the cases of rash and/or urticaria reported in premarketing clinical trials, almost a third were withdrawn from treatment because of the rash and/or systemic signs or symptoms associated with the rash. Clinical findings reported in association with rash include fever, leukocytosis, arthralgias, edema, carpal tunnel syndrome, respiratory distress, lymphadenopathy, proteinuria, and mild transaminase elevation. Most patients improved promptly with discontinuation of Fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely.


In premarketing clinical trials, 2 patients are known to have developed a serious cutaneous systemic illness. In neither patient was there an unequivocal diagnosis, but one was considered to have a leukocytoclastic vasculitis, and the other, a severe desquamating syndrome that was considered variously to be a vasculitis or erythema multiforme. Other patients have had systemic syndromes suggestive of serum sickness.


Since the introduction of Fluoxetine, systemic reactions, possibly related to vasculitis and including lupus-like syndrome, have developed in patients with rash. Although these reactions are rare, they may be serious, involving the lung, kidney, or liver. Death has been reported to occur in association with these systemic reactions.


Anaphylactoid reactions, including bronchospasm, angioedema, laryngospasm, and urticaria alone and in combination, have been reported.


Pulmonary reactions, including inflammatory processes of varying histopathology and/or fibrosis, have been reported rarely. These reactions have occurred with dyspnea as the only preceding symptom.


Whether these systemic reactions and rash have a common underlying cause or are due to different etiologies or pathogenic processes is not known. Furthermore, a specific underlying immunologic basis for these reactions has not been identified. Upon the appearance of rash or of other possibly allergic phenomena for which an alternative etiology cannot be identified, Fluoxetine should be discontinued.



Screening Patients for Bipolar Disorder and Monitoring for Mania/Hypomania


A major depressive episode may be the initial presentation of Bipolar Disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/ manic episode in patients at risk for Bipolar Disorder. Whether any of the symptoms described for clinical worsening and suicide risk represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for Bipolar Disorder; such screening should include a detailed psychiatric history, including a family history of suicide, Bipolar Disorder, and depression. It should be noted that Fluoxetine monotherapy is not approved for use in treating Bipolar I Disorder.


In U.S. placebo-controlled clinical trials for MDD, mania/hypomania was reported in 0.1% of patients treated with Fluoxetine and 0.1% of patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with Major Affective Disorder treated with other marketed drugs effective in the treatment of MDD [see Use in Specific Populations (8.4)].


In U.S. placebo-controlled clinical trials for OCD, mania/hypomania was reported in 0.8% of patients treated with Fluoxetine and no patients treated with placebo. No patients reported mania/hypomania in U.S. placebo-controlled clinical trials for bulimia. In all U.S. Fluoxetine clinical trials, 0.7% of 10,782 patients reported mania/hypomania [see Use in Specific Populations (8.4)].



Seizures


In U.S. placebo-controlled clinical trials for MDD, convulsions (or reactions described as possibly having been seizures) were reported in 0.1% of patients treated with Fluoxetine and 0.2% of patients treated with placebo. No patients reported convulsions in U.S. placebo-controlled clinical trials for either OCD or bulimia. In all U.S. Fluoxetine clinical trials, 0.2% of 10,782 patients reported convulsions. The percentage appears to be similar to that associated with other marketed drugs effective in the treatment of MDD. Fluoxetine should be introduced with care in patients with a history of seizures. There have been rare reports of prolonged seizures in patients on Fluoxetine receiving ECT treatment.



Altered Appetite and Weight


Significant weight loss, especially in underweight depressed or bulimic patients, may be an undesirable result of treatment with Fluoxetine.


In U.S. placebo-controlled clinical trials for MDD, 11% of patients treated with Fluoxetine and 2% of patients treated with placebo reported anorexia (decreased appetite). Weight loss was reported in 1.4% of patients treated with Fluoxetine and in 0.5% of patients treated with placebo. However, only rarely have patients discontinued treatment with Fluoxetine because of anorexia or weight loss [see Use in Specific Populations (8.4)].


In U.S. placebo-controlled clinical trials for OCD, 17% of patients treated with Fluoxetine and 10% of patients treated with placebo reported anorexia (decreased appetite). One patient discontinued treatment with Fluoxetine because of anorexia [see Use in Specific Populations (8.4)].


In U.S. placebo-controlled clinical trials for Bulimia Nervosa, 8% of patients treated with Fluoxetine 60 mg and 4% of patients treated with placebo reported anorexia (decreased appetite). Patients treated with Fluoxetine 60 mg on average lost 0.45 kg compared with a gain of 0.16 kg by patients treated with placebo in the 16 week double-blind trial. Weight change should be monitored during therapy.



Abnormal Bleeding


SNRIs and SSRIs, including Fluoxetine, may increase the risk of bleeding reactions. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding reactions related to SNRIs and SSRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of Fluoxetine and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation [see Drug Interactions (7.6)].



Hyponatremia


Hyponatremia has been reported during treatment with SNRIs and SSRIs, including Fluoxetine. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported and appeared to be reversible when Fluoxetine was discontinued. Elderly patients may be at greater risk of developing hyponatremia with SNRIs and SSRIs. Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations (8.5)]. Discontinuation of Fluoxetine should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.


Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. More severe and/or acute cases have been associated with hallucination, syncope, seizure, coma, respiratory arrest, and death.



Anxiety and Insomnia


In U.S. placebo-controlled clinical trials for MDD, 12% to 16% of patients treated with Fluoxetine and 7% to 9% of patients treated with placebo reported anxiety, nervousness, or insomnia.


In U.S. placebo-controlled clinical trials for OCD, insomnia was reported in 28% of patients treated with Fluoxetine and in 22% of patients treated with placebo. Anxiety was reported in 14% of patients treated with Fluoxetine and in 7% of patients treated with placebo.


In U.S. placebo-controlled clinical trials for Bulimia Nervosa, insomnia was reported in 33% of patients treated with Fluoxetine 60 mg, and 13% of patients treated with placebo. Anxiety and nervousness were reported, respectively, in 15% and 11% of patients treated with Fluoxetine 60 mg and in 9% and 5% of patients treated with placebo.


Among the most common adverse reactions associated with discontinuation (incidence at least twice that for placebo and at least 1% for Fluoxetine in clinical trials collecting only a primary reaction associated with discontinuation) in U.S. placebo-controlled Fluoxetine clinical trials were anxiety (2% in OCD), insomnia (1% in combined indications and 2% in bulimia), and nervousness (1% in MDD) [see Adverse Reactions (6.1)].



Use in Patients with Concomitant Illness


Clinical experience with Fluoxetine in patients with concomitant systemic illness is limited. Caution is advisable in using Fluoxetine in patients with diseases or conditions that could affect metabolism or hemodynamic responses.


Cardiovascular — Fluoxetine has not been evaluated or used to any appreciable extent in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were systematically excluded from clinical studies during the product’s premarket testing. However, the electrocardiograms of 312 patients who received Fluoxetine in double-blind trials were retrospectively evaluated; no conduction abnormalities that resulted in heart block were observed. The mean heart rate was reduced by approximately 3 beats/min.


Glycemic Control — In patients with diabetes, Fluoxetine may alter glycemic control. Hypoglycemia has occurred during therapy with Fluoxetine, and hyperglycemia has developed following discontinuation of the drug. As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with Fluoxetine is instituted or discontinued.


Acute Narrow-Angle Glaucoma—Mydriasis has been reported in association with Fluoxetine; therefore, caution should be used when prescribing Fluoxetine in patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma.



Potential for Cognitive and Motor Impairment


As with any CNS-active drug, Fluoxetine has the potential to impair judgment, thinking, or motor skills. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does not affect them adversely.



Long Elimination Half-Life


Because of the long elimination half-lives of the parent drug and its major active metabolite, changes in dose will not be fully reflected in plasma for several weeks, affecting both strategies for titration to final dose and withdrawal from treatment. This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with Fluoxetine and norFluoxetine following the discontinuation of Fluoxetine [see Clinical Pharmacology (12.3)].



Discontinuation of Treatment


During marketing of Fluoxetine, SNRIs, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these reactions are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with Fluoxetine. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Plasma Fluoxetine and norFluoxetine concentration decrease gradually at the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug.



Adverse Reactions



Clinical Trials Experience


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in practice.


Multiple doses of Fluoxetine had been administered to 10,782 patients with various diagnoses in U.S. clinical trials. In addition, there have been 425 patients administered Fluoxetine in panic clinical trials. Adverse reactions were recorded by clinical investigators using descriptive terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse reactions without first grouping similar types of reactions into a limited (i.e., reduced) number of standardized reaction categories.


In the tables and tabulations that follow, COSTART Dictionary terminology has been used to classify reported adverse reactions. The stated frequencies represent the proportion of individuals who experienced, at least once, an adverse reaction of the type listed. An adverse reaction was included if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that adverse reactions reported during therapy were not necessarily caused by it.


The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of adverse reactions in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.


Incidence in MDD, OCD, bulimia, and Panic Disorder placebo-controlled clinical trials (excluding data from extensions of trials) — Table 2 enumerates the most common adverse reactions associated with the use of Fluoxetine (incidence of at least 5% for Fluoxetine and at least twice that for placebo within at least 1 of the indications) for the treatment of MDD, OCD, and bulimia in U.S. controlled clinical trials and Panic Disorder in U.S. plus non-U.S. controlled trials. Table 3 provides combined data for the pool of studies that are provided separately by indication in Table 2.















































































































Table 2. Most Common Adverse Reactions: Incidence in Major Depressive Disorder, Obsessive-Compulsive Disorder, Bulimia, and Panic Disorder Placebo-Controlled Clinical Trials
Note:  Includes U.S. data for MDD, OCD, bulimia, and Panic Disorder clinical trials, plus non-U.S. data for Panic Disorder clinical trials.

a = Denominator used was for males only (N = 690 Fluoxetine MDD; N = 410 placebo MDD; N = 116 Fluoxetine OCD; N = 43 placebo OCD; N = 14 Fluoxetine Bulimia; N = 1 placebo Bulimia; N = 162 Fluoxetine Panic Disorder; N = 121 placebo Panic Disorder).

-- = Incidence less than 1%.
 Percentage of Patients Reporting Event
 MDDOCDBulimiaPanic Disorder
Body System/

Adverse Reaction
Fluoxetine

(N = 1728)   
Placebo

(N = 975)   
Fluoxetine   

(N = 266)
Placebo

(N = 89)   
Fluoxetine   

(N = 450)
Placebo

(N = 267)   
Fluoxetine   

(N = 425)
Placebo

(N = 342)   
Body as a Whole
   Asthenia95151121977
   Flu Syndrome341078355
Cardiovascular System   
   Vasodilatation325--211--
Digestive System
   Nausea21926132911127
   Diarrhea12818138694
   Anorexia11217108441
   Dry Mouth1071239644